Eli Lilly has announced a definitive agreement under which it will acquire Centessa Pharmaceuticals for approximately $6.3 billion upfront and a potential equity value of $1.5 billion.  Centessa is developing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the sleep-wake cycle to treat excessive daytime sleepiness and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!